SEC Form 3 · accession 0001193125-26-388127
Korsana Biosciences, Inc. · KRSA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan Violin
Officer — See Remarks · Director
Period of report
Sep 8, 2026
Accepted (ET)
Sep 10, 2026 · 5:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001755237
Table I — non-derivative securities
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F3 | $4.15 | holding | — | — | — | — | Oct 26, 2035 | Common Stock | 1,048,244 | — | D |
| Stock Option (Right to Buy)F1,F4 | $8.06 | holding | — | — | — | — | Jun 29, 2036 | Common Stock | 1,984,157 | — | D |
Explanation of responses
- F1Effective as of September 8, 2026 (the "Effective Time"), (i) Cariboos Merger Sub Corp., a wholly owned subsidiary of Cyclerion Therapeutics, Inc. ("Cyclerion"), merged with and into Korsana Biosciences, Inc. ("Pre-Merger Korsana"), with Pre-Merger Korsana continuing as a wholly owned subsidiary of Cyclerion and the surviving corporation of the merger (the "First Merger"), and (ii) immediately thereafter, Pre-Merger Korsana merged with and into Cariboos Merger Sub II, LLC, a second wholly owned subsidiary of Cyclerion ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Korsana Biosciences Operating Company, LLC (the "Second Merger" and, together with the First Merger, the "Merger"). At the Effective Time, Cyclerion changed its name to "Korsana Biosciences, Inc." (hereinafter, the "Issuer").
- F2Represents shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for the shares of Pre-Merger Korsana's common stock held by the Reporting Person prior to the Merger. Each share of Pre-Merger Korsana's restricted common stock held at the Effective Time was exchanged for 0.2074 restricted shares of the Issuer's common stock. Of these shares of common stock, 142,588 remain subject to forfeiture restrictions and vest in equal monthly installments through June 1, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
- F3Represents options to purchase shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for options of Pre-Merger Korsana held by the Reporting Person prior to the Merger. This option vested as to 25% on June 1, 2026 and vests in equal monthly installments thereafter through June 1, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
- F4Represents options to purchase shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for options of Pre-Merger Korsana held by the Reporting Person prior to the Merger. This option will vest as to 25% on June 18, 2027 and in equal monthly installments thereafter through June 18, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Remarks
Chief Executive Officer and President Exhibit 24 - Power of Attorney